BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a Phase 2 ready asset and a preclinical prodrug asset
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW)
("BullFrog AI" or the "Company"), a digital technology
company using machine learning to usher in a new era of precision medicine,
today announced a strategic partnership with the Sage Group, a leader in the provision of
strategic and transactional advice to healthcare and life science companies in
the pharmaceutical, diagnostics, medical device, biotech, regenerative
medicine, and cell and gene therapy fields.
The engagement will focus on
seeking joint venture (JV) opportunities to further advance BullFrog AI’s Phase
2 ready asset targeting glioblastoma, an aggressive form of brain cancer, as
well as the Company’s preclinical prodrug asset. The partnership will give
BullFrog AI access to the Sage Group’s clinical and regulatory expertise,
capital resources, and network of contacts, including innovators and large
"Glioblastoma is one of the
deadliest forms of cancer, with a five-year survival rate of less than seven
percent,” said BullFrog AI’s founder and CEO, Vin Singh. “With the Sage Group’s
support, we look forward to identifying the right partner to help us advance
clinical development of our oncology programs globally in an effort to bring a
revolutionary new treatment option to glioblastoma patients.”
The market for glioblastoma
treatment is expected to surpass $10 billion by 2030, up from $5.1 billion in
2020, according to a 2022 analysis by a Vision Research Report. BullFrog AI has
previously announced the grant of exclusive licenses from JHU for a novel
formulation of mebendazole that has been evaluated in two clinical trials for
glioblastoma, and for a novel prodrug of mebendazole with improved
About BullFrog AI
BullFrog AI is a digital technology
company using machine learning to usher in a new era of precision medicine.
Through its collaborations with leading research institutions, including Johns
Hopkins University, BullFrog AI is at the forefront of AI-driven drug
development. Using its proprietary bfLEAP™ artificial intelligence platform,
BullFrog AI aims to enable the successful development of pharmaceuticals and
biologics by predicting which patients will respond to therapies in development.
BullFrog AI is deploying bfLEAP™ for use at several critical stages of
development with the intention of streamlining data analytics in therapeutics
development, decreasing the overall development costs by decreasing failure
rates for new therapeutics, and impacting the lives of countless patients that
may seek to receive the therapies they need.
For more information visit
Safe Harbor Statement
This press release contains
forward-looking statements. We base these forward-looking statements on our
expectations and projections about future events, which we derive from the
information currently available to us. Such forward-looking statements relate
to future events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings; and our
business prospects and opportunities. You can identify forward-looking
statements by those that are not historical in nature, particularly those that
use terminology such as "may," "should,"
"expects," "anticipates," "contemplates,"
"estimates," "believes," "plans,"
"projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various factors,
including: our ability to change the direction of the Company; our ability to
keep pace with new technology and changing market needs; and the competitive
environment of our business. These and other factors may cause our actual
results to differ materially from any forward-looking statement.
Forward-looking statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time to time by
us or our representatives, may not occur, and actual events and results may
differ materially and are subject to risks, uncertainties, and assumptions
about us. We are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions, the
forward-looking events discussed in this press release and other statements
made from time to time by us or our representatives might not occur.